Skip to main content
Sonoma Pharmaceuticals, Inc. logo

Sonoma Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · SNOA ISIN · US83558L2043 US Manufacturing
Open in API
Filings indexed 951 across all filing types
Latest filing 2021-11-15 Interim / Quarterly Rep…
Country US United States of America
Listing US SNOA

About Sonoma Pharmaceuticals, Inc.

https://sonomapharma.com/

Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and commercializes products based on its patented Microcyn® Technology, a stabilized hypochlorous acid (HOCl) platform. With over 20 years of experience, the company produces a range of prescription and over-the-counter solutions for advanced wound care, dermatology, animal health, and eye care. Its products are designed to manage various conditions by promoting healing and reducing the risk of infection. The portfolio serves healthcare professionals in settings like hospitals and nursing homes, as well as consumers for at-home use.

Recent filings

Filing Released Lang Actions
FORM 10-Q
Interim / Quarterly Report Q2 2021
2021-11-15 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement (a 20-year license and distribution agreement) with Dyamed Biotech Pte, Ltd. There are no financial statements or quarterly/annual financial results presented, nor is this a transcript or management discussion. The document is not an announcement of a report publication but a regulatory filing disclosing a significant contract. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is 3810 characters, which is relatively short and consistent with a Form 8-K filing. Confidence is high due to the clear identification of the form and content type.
2021-11-09 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated September 15, 2021, for Sonoma Pharmaceuticals, Inc. It reports the submission of matters to a vote of security holders at the annual meeting, including election results for a director, advisory vote on executive compensation, ratification of the independent auditor, and approval of an equity incentive plan. It also discloses a board member retirement and committee realignment. The content focuses on official voting results and board changes following the annual meeting. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA), as it provides official shareholder vote outcomes and related governance updates. The document is not a full annual report, proxy statement, or management discussion, but a current report specifically reporting voting results and related board changes. Confidence is high given the clear SEC Form 8-K format and detailed voting results.
2021-09-21 English
FORM 8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated September 3, 2021. It references incorporation by reference into a shelf registration statement (Form S-3) and includes exhibits such as legal opinions and consents. The content is typical of a regulatory announcement rather than a full financial report or earnings release. The document length is 3543 characters, which is relatively short and does not contain substantive financial data or detailed management discussion. It primarily serves as a regulatory filing to disclose certain events and exhibits. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-09-03 English
FORM 424B3
Capital/Financing Update Classification · 95% confidence The document is a Form 424B3 prospectus supplement filed pursuant to Rule 424(b)(3) under the Securities Act of 1933. It details an 'At The Market Offering' (ATM) of common stock by Sonoma Pharmaceuticals, Inc., including terms of the offering, use of proceeds, risk factors, and plan of distribution. The document is a registration and offering prospectus supplement related to capital raising activities, not a financial report, earnings release, or management discussion. It is specifically about a capital/financing update and securities offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief notice, supporting a high confidence level.
2021-09-03 English
OTHER PROXY INFORMATION
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a letter urging shareholders to vote their proxies for an upcoming annual meeting. It references proxy materials, the importance of voting, and mentions proposals including election of a director, executive compensation approval, and auditor ratification. The document is short (1922 characters) and does not contain financial data or detailed report content. It is clearly a solicitation or reminder related to proxy voting, which fits the category of Proxy Solicitation & Information Statement (PSI).
2021-08-30 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.